1. INTRODUCTION
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.4. Industry Value Chain Analysis
5. MIDDLE EAST AND AFRICA (MEA) ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY TYPE OF DISEASE
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others
6. MIDDLE EAST AND AFRICA (MEA) ANTI-RHEUMATIC DRUG MARKET ANALYSIS, DRUG CLASS
6.1. Introduction
6.2. Disease-modifying Anti-Rheumatic Drugs (DMARDs)
6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.4. Corticosteroids
6.5. JAK inhibitor
6.6. Others
7. MIDDLE EAST AND AFRICA (MEA) ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY SALES CHANNEL
7.1. Introduction
7.2. Prescription
7.3. Over-The-Counter (OTC)
8. MIDDLE EAST AND AFRICA (MEA) ANTI-RHEUMATIC DRUG MARKET ANALYSIS, BY COUNTRY
8.1. Introduction
8.2. Saudi Arabia
8.3. Israel
8.4. Nigeria
8.5. Ethiopia
8.6. Egypt
8.7. Iran
8.8. Turkey
8.9. South Africa
8.10. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. COMPANY PROFILES
10.1. AbbVie Inc.
10.2. Amget Inc.
10.3. Johnson and Johnson
10.4. Pfizer Inc.
10.5. GlaxoSmithKline plc
10.6. Merck & Co., Inc.
10.7. Eli Lilly and Company
10.8. Novartis AG
10.9. Celgene Corporation (Bristol-Myers Squibb)